MENVEO® Pregnancy Registry: an Observational Study on the Safety of MENVEO Exposure in Pregnant Women and Their Offspring
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 27 Oct 2017
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
- Indications Meningococcal infections
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; Novartis
- 24 Oct 2017 Status changed from recruiting to active, no longer recruiting.
- 30 Dec 2014 Planned End Date changed from 1 Feb 2019 to 1 Aug 2018 as reported by ClinicalTrials.gov record.
- 30 Dec 2014 Planned primary completion date changed from 1 Jul 2018 to 1 Aug 2018 as reported by ClinicalTrials.gov record.